

# *Review Article*

# **Comparison of Cryotherapy and Topical Salicylic Acid in Common Warts: A Systematic Review and Meta-Analysis**

Dipika Chaudhary (),<sup>1,2</sup> Yan Sun (),<sup>1,2</sup> and Xinghua Gao ()<sup>1,2</sup>

<sup>1</sup>Department of Dermatology, The First Hospital of China Medical University, Shenyang, China <sup>2</sup>NHC Key Laboratory of Immunodermatology, Ministry of Education Key Laboratory of Immunodermatology, National Joint Engineering Research Center for Diagnosis and Treatment of Immunologic Skin Diseases, The First Hospital of China Medical University, Shenyang, China

Correspondence should be addressed to Yan Sun; sunyan805@163.com and Xinghua Gao; gaobarry@hotmail.com

Received 22 April 2023; Revised 5 October 2023; Accepted 20 November 2023; Published 27 November 2023

Academic Editor: Shijun Shan

Copyright © 2023 Dipika Chaudhary et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Background.* Common warts are most common complaint among children and adults caused by human papillomavirus (HPV). Cryotherapy and topical salicylic acid are common therapies. *Objective.* To compare the efficacy and safety of cryotherapy and topical salicylic acid in common warts. *Methods.* Randomized controlled trials (RCTs) comparing cryotherapy and topical salicylic acid treatment in patients with common warts were searched by using PubMed, Embase, Google Scholar, and Cochrane Database of Systematic Reviews up to Oct 20, 2021. The keywords were "common warts/verruca," "cryotherapy," and "salicylic acid." The language was restrained to English. No age or gender limitation was conducted. The outcomes were complete remission of all warts at different observation times, recurrence rates, and side effects. Study-specific effect sizes were pooled by using 976 patients randomized into the cryotherapy group or salicylic acid group were included. Of whom, 487 patients received cryotherapy, while 489 received salicylic acid treatment. With the fixed-effects model, the pool effect of complete clearance of warts at 12 weeks comparing cryotherapy and topical salicylic acid was not statistically significant (RR = 0.99 (0.84–1.17),  $I^2 = 0\%$ ). *Conclusion.* Comparable efficacy of cryotherapy and topical salicylic acid was conducted in common wart treatment. More high-quality pieces of evidence with more samples are needed to confirm the results for further recommendations.

# 1. Introduction

Common warts are widespread benign skin conditions caused by human papilloma virus (HPV) [1, 2]. They frequently affect the hands as well as feet but also in other sites. They are widespread in general population, estimated to affect approximately 7–12% populations worldwide [3]. There are more than 200 types of HPV identified, most of which are DNA viruses infecting epithelial cells [4]. They affect any area on the skin and mucous membrane and are transmitted by direct or indirect contact. Although warts disappear spontaneously without treatment in 15–63% of cases in years [1], patients usually seek treatments to avoid physical discomfort and debilitating appearance. There are several treatment options available for common warts, including cryotherapy, topically applied treatments, surgical curettage, and local hyperthermia [5]. Topical salicylic acid is the first-line treatment choice of common warts, and further treatment with cryotherapy is indicated as second-line therapy without clearance of warts [6]. Cryotherapy is usually applied on lesions at intervals of 2–4 weeks by using liquid nitrogen, which works by freezing tissue, damaging intended cells and their vascular supply, and is also expected to stimulate the immune system which leads to resolution of warts [4]. Salicylic acid is comparatively cheaper, readily available, and self-applicable topical treatment. It is effective for warts with limited adverse effects but requires daily application for several weeks [4]. Local hyperthermia is a patent device held by our team. It destroyed HPV-infected tissue by antigen-presenting cells, T cells, and natural killer cells at  $44^{\circ}C$  [7]. Our previous study including 1027 patients showed comparable complete clearance rates of plantar warts by local hyperthermia and cryotherapy (50.9% vs. 54.3%) 3 months after treatment [8].

Several studies reported cryotherapy and topical salicylic acid treatment in common warts. But the results were controversial. Therefore, we conducted the present systemic review and meta-analysis in order to compare the efficacy as well as safety of cryotherapy and topical salicylic acid in common warts.

#### 2. Methods

The procedure followed the recommendations for the Preferred Reporting Items for Systematic Review (PRISMA) [9] and the Cochrane Handbook for Systematic Reviews of Interventions (Cochrane Collaboration, 2011).

2.1. Search Strategy. Randomized controlled trials (RCTs) of cryotherapy and topical salicylic acid treatment in common warts of healthy, nonimmunocompromised adults, and/or children were searched by using PubMed, Google Scholar, Embase, and Cochrane Database of Systematic Reviews up to Oct 20, 2021. The keywords were "common warts/verruca," "salicylic acid," and "cryotherapy." The language was restrained to English. No age or gender limitation was conducted.

2.2. Study Selection and Data Extraction. All studies with cure rates of both cryotherapy and salicylic acid treatments were selected by screening abstracts or even full text. Studies with recurrent/recalcitrant warts, genital warts, immunocompromised patients (such as agammaglobulinemia), impaired healing (such as diabetics), cold intolerance (such as cold urticaria or Raynaud's syndrome), blood dyscrasias of unknown origin, cryoglobulinemia, cryofibrinogenemia, and connective or autoimmune disease were excluded. Guidelines, review articles, commentary, salicylic acid, or cryotherapy used as adjuvant therapy and treatments other than salicylic acid and cryotherapy were also omitted. Relative data, including the first author, year of publication, size/number of warts, age/gender of patients, and treatment procedure, were extracted by screening the full text. Two reviewers, Dipika Chaudhary and Anupama Bishwokarma, performed the procedure independently and discussed as well as consulted with a third reviewer, Archana Shrestha, with disagreements.

2.3. Quality Assessment. Qualities of all the studies included were evaluated using the revised Cochrane risk-of-bias tool (RoB, version 2) for randomized trials. RoB 2 is designed into a fixed set of domains of bias, aimed at focusing various traits of trial designing, conducting, and reporting. There are 5 domains in RoB: biases as a result of the randomization process, biases owing to deviations from intended interventions, biases as a result of missing outcome data, biases

in the measurement of the outcome, and bias during selection of the reported result. In each domain, there are a series of questions (signaling questions) focused on obtaining information regarding features of the trial, which are significant to the risk of bias. For each domain, a response (yes, probably yes, probably no, no, or no information) was defined according to each study. Then, the quality was evaluated by the algorithm as a low risk, some concerns, or a high risk [10].

2.4. Outcomes. Complete remission of all warts was described as the complete restoration of normal skin. The outcomes were complete remission of all warts at different observation times, recurrence rates, and side effects.

2.5. Statistical Analysis. All of the statistical analysis was conducted by using R version 4.0.3 (the R Foundation for Statistical Computing, Vienna, Austria) [11]. Study-specific effect sizes were pooled by using the fixed-effects model [12] and the Mantel-Haenszel method.  $I^2$  was used to assess heterogeneity of studies. The forest plot, funnel plot, and pooled relative risk (RR) were conducted by using the "meta" package [13]. Robustness was performed by leave-one-out sensitivity analysis in the "metainf" function of the meta package.

#### 3. Results

3.1. Eligible Studies. A total of 617 studies were retrieved. After screening titles as well as abstracts of the yielded studies, 208 duplicates and 269 studies which failed to meet the inclusion criteria were excluded. Thus, the remaining 140 articles were selected for full-text review. Subsequently, 133 studies with recurrent warts/recalcitrant warts, genital warts, guidelines or review articles, commentary, salicylic acid, or cryotherapy used as adjuvant therapy or treatments other than salicylic acid and cryotherapy were excluded. At last, 7 studies were selected for the following meta-analysis [14–20] (Figure 1).

3.2. Basic Characteristics and Interventions of the Studies Included. A total of 976 patients with common warts were treated with either cryotherapy or salicylic acid. Their age ranged from 4 to 79 years old. Sample size ranged from 70 [18] to 240 [14] (Table 1).

A total of 487 patients were treated with cryotherapy, which was performed 4–6 sessions at hospital with an interval of 2-3 weeks. The other 489 patients were treated with 20–50% salicylic acid, which was applied topically by themselves every day for a maximum of 8–12 weeks. The follow-up periods were 6 weeks for 1 study [17], 12 weeks for 5 studies [14–17, 19], and 6 months for the other one [20] (Table 2).

*3.3. Quality Assessment.* Only one study was categorized as a low risk [18], whereas all other studies had a high-risk publication bias [14–17, 19, 20]. Out of the 7 studies, low risk




FIGURE 1: Flowchart of the selection procedure.

	Year	Size of warts (cm in diameter)	No. of warts	No. of people		Mean age		Gender (male/female)	
Study				Cryotherapy	Salicylic acid	Cryotherapy	Salicylic acid	Cryotherapy	Salicylic acid
Bunney	1976	_	_	99	95	_	_	_	_
Steele	1988	0.3-0.9	5	66	60	—	_	_	_
Bruggink	2010	<1	<6, ≥6	80	84	—	_	35/45	30/54
Cockayne	2011	—	3.7	117	123	30.1	30.2	30/84	50/73
Rosniza	2017	>1, 0.5–1, <0.5	3.63	39	41	37.87	34.44	17/22	18/23
Muhamad	2018	—	_	35	35	$22.54 \pm 8.729$	$26.91 \pm 11.44$	15/20	15/20
Qamar	2018	<1, 1-1.5	$2.48 \pm 1.35$	51	51	$24.63 \pm 5.30$	$25.80 \pm 6.69$	_	_

was reported in 3 studies in the randomization process [15, 17, 18], 3 studies in deviations from intended interventions [14, 15, 18], 5 studies in missing outcome data [14, 17–20], 1 study in measurement of the outcome [18], and all studies in selection of the reported results [14–20] (Figure 2).

				TABLE 2: Ir	TABLE 2: Interventions and outcomes of the included studies.	outcomes of the	e included stu					
		Τ	Treatment	Dur	Duration	Percentage recovered	recovered	Side effect	ect	Recurrence rate (%)	rate (%)	
Study	Year	Cryotherapy	Salicylic acid	Cryotherapy	Salicylic acid	Cryotherapy	Salicylic acid	Cryotherapy Salicylic acid	Salicylic acid	Cryotherapy	Salicylic acid	Outcomes
Bunney	1976	1976 4-5 sessions	Daily self-application of SA/LA paint for 3 weeks apart 12 weeks	3 weeks apart	Daily up to a maximum of 12 weeks	67.3	68.6	I	I	I	Ι	Cure rate at 12 weeks
Steele	1988	Up to 6 sessions	Daily self-application of SA/LA paint for 1 week 12 weeks	1 week apart	Daily up to a maximum of 12 weeks	Hand warts = 62.5 Plantar warts = 57.7	Hand warts = 60.5 Plantar warts = 40.9	I	I	0/66 (0%)	2/60 (3.33%)	Cure rate at 6 months
Bruggink 2010	2010	Up to 6 sessions	Patient self-application with 40% SA	Once every 2 weeks	Daily until warts are completely gone	39	24	2/80	9/84	I	I	Complete clearance rate at 13 weeks
Cockayne 2011	2011	Up to 4 sessions	Patient self-application with 50% SA	2-3 weeks apart	Daily up to a maximum of 8 weeks	13.6	14.3	14/28	13/28	2/117 (1.7%)	2/123 (1.6%)	Complete clearance rate at 12 weeks
Rosniza	2017	Maximum of 4 sessions	Self-application of 20% SA	2 weeks apart	Daily up to a maximum of 12 weeks	33.3	26.8	I	I	I	I	Complete clearance rate at 12 weeks
Muhamad 2018	2018	Up to 5 sessions	Self-application with 40% SA	2-3 weeks apart	Daily up to a maximum of 8 weeks	66.7	80	I	I	I	I	Complete clearance rate at 12 weeks
Qamar	2018	Up to 3 sessions	Self-application of 40% SA	2 weeks apart	Daily up to a maximum 6 weeks	56.9	66.7	I	I	I	I	Complete clearance rate at 6 weeks
SA/LA = sali	cylic acit	SA/LA = salicylic acid/lactic acid; SA = salicylic acid	= salicylic acid.									




FIGURE 2: Quality assessments of the included studies.

#### 3.4. Outcome Assessments

3.4.1. Complete Remission Rate of All Warts at 6 Weeks. One study reported the complete remission rate of all warts between cryotherapy and salicylic acid treatment at 6 weeks [17]. The complete remission rate was comparable in the salicylic acid group (66.7%) and the cryotherapy group (56.9%) (p = 0.415).

3.4.2. Complete Remission Rate of All Warts at 12 Weeks. Four studies compared the complete remission rate of all warts treated by cryotherapy or salicylic acid at 12 weeks [14, 16, 18, 19]. With the fixed-effects model, there was not any statistical significance between the two groups, RR = 0.99 (0.84–1.17) with a heterogeneity of  $I^2 = 0\%$  (Figure 3).

3.4.3. Complete Remission Rate of All Warts at 13 Weeks. One study reported the complete remission rate of all warts between cryotherapy and salicylic acid treatment at 13 weeks [15]. The cure rate was observed to be higher in the cryotherapy group (39%) than that in the salicylic acid group (24%) (p < 0.05). The relative risk between cryotherapy and salicylic acid was 1.6 (95% CI: 1.0–2.6). 3.4.4. Complete Remission Rate of All Warts at 24 Weeks. Only 1 study reported the complete remission rate of all warts between cryotherapy and salicylic acid treatment at 24 weeks [20]. For common warts in hands, the complete remission rate was 62.5% in the cryotherapy group and 60.5% in the salicylic acid group (p < 0.05); for those in feet, the complete remission rate was 57.7% in the cryotherapy group and 40.9% in the salicylic acid group (p < 0.05).

3.4.5. Recurrence Rate. Two studies mentioned the recurrence rate at 6 months [18, 20]. In Cockayne's study, 4 patients reported recurrence of warts in their original positions, and the recurrence rate was comparable between the cryotherapy group (1.7%, 2/117) and the salicylic acid group (1.6%, 2/123) [18]. In Steele's study, only 2 patients (3.33%, 2/60) had recurrence of warts in the salicylic acid group, which had a higher recurrence rate than that in the cryotherapy group (0%, 0/66) [20].

3.4.6. Side Effects. Two studies reported side effects between cryotherapy and salicylic acid on warts [15, 18]. In Cockayne's study, patients after cryotherapy suffered from more side effects than those after topical salicylic acid treatment. The side effects included pain, scarring, blistering, crust, pigmentation, and irritation. A total of 28 adverse events

Study	Cryotl Events	herapy Total	Salicyl Events	ic acid Total	Risk Ratio	RR	95%-CI	Weight (%)
Bunney, 1976	68	99	64	95		1.02	[0.84; 1.24]	56.1
Cockayne, 2011	15	110	17	119		0.95	[0.50; 1.82]	14.0
Rosniza, 2017	13	39	11	41		— 1.24	[0.63; 2.43]	9.2
Muhamad, 2018	20	30	24	30		0.83	[0.61; 1.14]	20.6
Fixed effect model Heterogeneity: $I^2 =$		278 54		285		0.99	[0.84; 1.17]	100.0
	070, p = 0.0	, <u>-</u>			0.5 1	2		

FIGURE 3: Comparison of complete clearance of common warts at 12 weeks between cryotherapy and salicylic acid. The forest plot was generated using the "meta" package of R.

were reported, including 1 serious one (not related to the treatment in the salicylic acid group) and 27 nonserious ones. For the remaining 27 reported events, 14 were in the cryotherapy group (2 related events of blisters, 7 were unrelated, and 5 unlikely to be related) and 13 were in the salicylic acid group (9 unrelated and 4 unlikely to be related) [18]. In Bruggink's study, more patients treated with salicylic acid (54%) reported significant treatment burden than those with cryotherapy (31%) (p = 0.040), such as pain, blistering, and scarring [15].

3.5. Leave-One Out Sensitivity Analysis. The leave-one out sensitivity analysis was conducted by eliminating one study at a time in sequential order, pooled RR was recalculated for the remaining studies, and the effect of removing each study based on the  $I^2$  statistic was evaluated. It showed how an individual study affected the overall estimate of the rest ones [21]. The pooled RRs did not change significantly, ranging from 1.0487 (95% CI: 0.9183; 1.1976) to 1.1455 (95% CI: 0.9694; 1.3536).  $I^2$  indicated small heterogeneity among studies, varied from 0.0% to 20.3% (Table 3).

3.6. Publication Bias. The publication bias of the 7 studies was shown in the funnel plot (Figure 4). The points were few but scattered symmetrically, which indicated lower publication bias. We could not use Egger's test to evaluate the potential publication bias because fewer studies were involved in meta-analysis (<10) [22].

## 4. Discussion

Cryotherapy commonly uses liquid nitrogen with a temperature of  $-196^{\circ}$ C, which works by either necrotic destruction of HPV-infected keratinocytes or local inflammation triggering cell-mediated response [6]. The efficacy varies in mode of application, treatment intervals, and freeze times. Increased efficacy is conducted by aggressive cryotherapy, accompanied with higher risks of side effects, such as pain, scarring, blistering, crust, pigmentation, and irritation [23]. Hyperpigmentation or hypopigmentation may occur, especially in dark-skinned patients [18]. Moreover, side effects are more common in treatment

regimens with a shorter interval. Therefore, preventive measures must be taken during application of cryotherapy adjacent to the cutaneous nerves, nail apparatus, and tendons, as well as in patients with arterial or venous circulation impairment.

Topical salicylic acid is a keratolytic agent which gradually destroys the epidermis infected by virus, and the mild irritation may activate an immune response. The concentration preparation may vary from 10% to 60%. The available preparations over the counter are 17% salicylic acid combined with a flexible collodion base or as 20%, 40%, and 50% in Vaseline ointment [6]. Before each application of topical salicylic acid, warts should be soaked in warm water for approximately 5 minutes, and then, the dead tissues should be removed using a file. Patients should be very careful when paring in order to avoid abrading the adjacent normal skin, as it may spread the disease.

Both treatments are destructive therapy. As we know, there were 4 studies with meta-analysis reported the comparison of effectiveness and cost between cryotherapy and topical salicylic acid in common warts. All of them showed no significant difference in efficacy [4, 24, 25]. Our findings were consistent with those of previous ones, but the number of patients and studies included were more than theirs. Nowadays, topical salicylic acid is first-line therapy, while cryotherapy is second-line therapy for common warts [18]. Therefore, we suggest that both topical salicylic acid and cryotherapy should be the first choice for common warts according to the present results.

Furthermore, salicylic acid is convenient and cheap but requires daily application up to 8 weeks. Therefore, patient compliance plays a major role. Moreover, all salicylic acid can cause chemical burns so it should not be applied to poor healing areas such as neuropathic feet, except for few very low-strength ones. Thus, they are forbidden to apply on the face because of risk of irritant burning [26]. Since both salicylic acid and cryotherapy have a higher probability of adverse reactions and recurrence, photodynamic therapy might be a better choice with better efficacy, fewer adverse reactions, and lower recurrence rates [27]. The mechanism might be associated with antiviral activity, local immunity, and reactive oxygen species [28]. Therefore, patients could choose either treatment as their convenience.

Omitting Steele, 19881.0974[0.9515; 1.2657]0.20170.00950.097320.3Omitting Bruggink, 20101.0487[0.9183; 1.1976]0.48300.00000.00000.0Omitting Cockayne, 20111.1174[0.9818; 1.2720]0.09300.00930.096221.5Omitting Rosniza, 20171.0961[0.9615; 1.2495]0.16990.00890.094220.3Omitting Muhamad, 20181.1413[0.9921; 1.3129]0.06440.00000.00000.0Omitting Qamar, 20181.0923[0.9475; 1.2592]0.22380.00800.089217.1		RR	95% CI	p value	Tau <sup>2</sup>	Tau	$I^2$ (%)
Omitting Bruggink, 20101.0487[0.9183; 1.1976]0.48300.00000.00000.0Omitting Cockayne, 20111.1174[0.9818; 1.2720]0.09300.00930.096221.5Omitting Rosniza, 20171.0961[0.9615; 1.2495]0.16990.00890.094220.3Omitting Muhamad, 20181.1413[0.9921; 1.3129]0.06440.00000.00000.0Omitting Qamar, 20181.0923[0.9475; 1.2592]0.22380.00800.089217.1	Omitting Bunney, 1976	1.1455	[0.9694; 1.3536]	0.1104	0.0084	0.0915	19.0
Omitting Cockayne, 20111.1174[0.9818; 1.2720]0.09300.00930.096221.5Omitting Rosniza, 20171.0961[0.9615; 1.2495]0.16990.00890.094220.3Omitting Muhamad, 20181.1413[0.9921; 1.3129]0.06440.00000.00000.0Omitting Qamar, 20181.0923[0.9475; 1.2592]0.22380.00800.089217.1	Omitting Steele, 1988	1.0974	[0.9515; 1.2657]	0.2017	0.0095	0.0973	20.3
Omitting Rosniza, 20171.0961[0.9615; 1.2495]0.16990.00890.094220.3Omitting Muhamad, 20181.1413[0.9921; 1.3129]0.06440.00000.00000.0Omitting Qamar, 20181.0923[0.9475; 1.2592]0.22380.00800.089217.1	Omitting Bruggink, 2010	1.0487	[0.9183; 1.1976]	0.4830	0.0000	0.0000	0.0
Omitting Muhamad, 20181.1413[0.9921; 1.3129]0.06440.00000.00000.0Omitting Qamar, 20181.0923[0.9475; 1.2592]0.22380.00800.089217.1	Omitting Cockayne, 2011	1.1174	[0.9818; 1.2720]	0.0930	0.0093	0.0962	21.5
Omitting Qamar, 20181.0923[0.9475; 1.2592]0.22380.00800.089217.1	Omitting Rosniza, 2017	1.0961	[0.9615; 1.2495]	0.1699	0.0089	0.0942	20.3
	Omitting Muhamad, 2018	1.1413	[0.9921; 1.3129]	0.0644	0.0000	0.0000	0.0
Pooled estimate 1.1040 [0.9700; 1.2565] 0.1339 0.0028 0.526 7.4	Omitting Qamar, 2018	1.0923	[0.9475; 1.2592]	0.2238	0.0080	0.0892	17.1
	Pooled estimate	1.1040	[0.9700; 1.2565]	0.1339	0.0028	0.526	7.4

TABLE 3: Leave-one out sensitivity analysis.

RR = relative risk; CI = confidence interval.




FIGURE 4: Publication bias of the included studies. The funnel plot was generated using the "meta" package of R. The vertical axis represents the standard error, and the horizontal axis represents the risk ratio of all the included studies.

However, there were some limitations in this review. On the one hand, although the funnel plot was symmetrically distributed, it was difficult to conclude that publication bias was absent because only 7 RCTs were included. On the other hand, the individual study quality assessment indicated a high risk of publication bias, except for one. Therefore, we acknowledge that our metaanalysis could have been affected by publication bias, with inclusion of disproportionately higher number of studies with hypothesized outcomes. Moreover, topical salicylic acid was self-administered by patients themselves so it was bound to have some variations in compliance, as it would reduce the efficacy compared to treatments applied by health professions.

# 5. Conclusion

The present study concluded a comparable efficacy of cryotherapy and topical salicylic acid for the treatment of common warts. More pieces of evidence with higher qualities and sample sizes are needed to confirm the results for further recommendations.

## **Data Availability**

The data used to support the findings of this study are included within the article; further inquiries can be directed to the corresponding author upon request.

# **Conflicts of Interest**

The authors declare that they have no conflicts of interest.

#### Acknowledgments

The authors would like to thank the following people for their assistance, contributions, and their immense help in this study: Anupama Bishwokarma and Archana Shrestha for study selection and data extraction; Bikram Adhikari for statistical analysis.

#### References

- A. Kaur, B. K. Brar, S. Kumar, S. K. Brar, A. S. Boparai, and N. Puri, "A randomized comparative study of MIP and MMR vaccine for the treatment of cutaneous warts," *Indian Journal* of *Dermatology*, vol. 66, no. 2, pp. 151–158, 2021.
- [2] J. Liu, H. Li, F. Yang et al., "Epidemiology and clinical profile of cutaneous warts in Chinese college students: a crosssectional and follow-up study," *Scientific Reports*, vol. 8, no. 1, Article ID 15450, 2018.
- [3] P. Zhu, R. Q. Qi, Y. Yang et al., "Clinical guideline for the diagnosis and treatment of cutaneous warts," *Journal of Evidence-Based Medicine*, vol. 15, no. 3, pp. 284–301, 2022.
- [4] A. Oganesyan, T. Sivesind, and R. Dellavalle, "From the Cochrane library: topical treatments for cutaneous warts," *JMIR Dermatology*, vol. 4, no. 2, Article ID e33900, 2021.
- [5] D. Abeck, L. Tetsch, M. Luftl, and T. Biedermann, "Extragenital cutaneous warts- clinical presentation, diagnosis and treatment," *JDDG: Journal der Deutschen Dermatologischen Gesellschaft*, vol. 17, no. 6, pp. 613–634, 2019.
- [6] J. C. Sterling, S. Gibbs, S. S. Haque Hussain et al., "British Association of Dermatologists' guidelines for the management of cutaneous warts," *British Journal of Dermatology*, vol. 171, no. 4, pp. 696–712, 2014.
- [7] J. L. Chen, S. Zheng, Y. Yang, X. H. Gao, R. Q. Qi, and H. D. Chen, "Successful treatment of extensive flat warts with local hyperthermia: a case report," *Dermatologic Therapy*, vol. 33, no. 6, Article ID e14525, 2020.
- [8] W. Huo, Y. L. Gao, H. Y. Wang et al., "Local hyperthermia versus cryotherapy for treatment of plantar warts: a prospective multi-centre non-randomized concurrent controlled clinical trial," *Acta Dermato-Venereologica*, vol. 102, Article ID adv00655, 2022.
- [9] D. V. Parums, "Editorial: review articles, systematic reviews, meta-analysis, and the updated preferred reporting Items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines," *Medical Science Monitor*, vol. 27, Article ID e934475, 2021.
- [10] J. A. C. Sterne, J. Savović, M. J. Page et al., "RoB 2: a revised tool for assessing risk of bias in randomised trials," *BMJ*, vol. 366, p. 14898, 2019.
- [11] P. Mair, E. Hofmann, K. Gruber, R. Hatzinger, A. Zeileis, and K. Hornik, "Motivation, values, and work design as drivers of participation in the R open source project for statistical computing," *Proceedings of the National Academy of Sciences* of the United States of America, vol. 112, no. 48, pp. 14788– 14792, 2015.
- [12] J. M. Lamo-Espinosa, G. Mariscal, J. Gomez-Alvarez, and M. San-Julian, "Efficacy and safety of arthroscopy in femoroacetabular impingement syndrome: a systematic review and meta-analysis of randomized clinical trials," *Scientific Reports*, vol. 13, no. 1, Article ID 16493, 2023.
- [13] G. Zhiting, T. Jiaying, H. Haiying, Z. Yuping, Y. Qunfei, and J. Jingfen, "Cardiovascular disease risk prediction models in the Chinese population- a systematic review and metaanalysis," *BMC Public Health*, vol. 22, no. 1, p. 1608, 2022.
- [14] S. Cockayne, C. Hewitt, K. Hicks et al., "Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): a randomised controlled trial," *BMJ*, vol. 342, no. jun07 1, p. d3271, 2011.
- [15] S. C. Bruggink, J. Gussekloo, M. Y. Berger et al., "Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: randomized controlled

trial," *Canadian Medical Association Journal*, vol. 182, no. 15, pp. 1624–1630, 2010.

- [16] M. H. Bunney, M. W. Nolan, and D. A. Williams, "An assessment of methods of treating viral warts by comparative treatment trials based on a standard design," *British Journal of Dermatology*, vol. 94, no. 6, pp. 667–679, 1976.
- [17] H. Y. Qamar, M. Batool, and I. Hanif, "Comparison of effecacy of 40% topical salicylic acid and cryotherapy in patients with palmoplantar warts," *Journal of Medicine*, *Physiology and Biophysics*, vol. 43, pp. 28–32, 2018.
- [18] N. Muhamad and A. A. Sulaiman, "Comparative study between cryotherapy and salicylic acid in the treatment of plantar warts in Erbil- Iraq," ZANCO Journal of Medical Sciences, vol. 22, no. 1, pp. 65–72, 2018.
- [19] S. Rosniza and N. Z. Azizan, "Liquid nitrogen cryotherapy versus 20% salicylic acid ointment for the treatment of plantar warts," *Malaysian Journal of Dermatology*, vol. 38, pp. 43–51, 2017.
- [20] K. Steele and W. G. Irwin, "Liquid nitrogen and salicylic/lactic acid paint in the treatment of cutaneous warts in general practice," *Journal of the Royal College of General Practitioners*, vol. 38, no. 311, pp. 256–258, 1988.
- [21] S. C. Rayol, J. Van den Eynde, L. R. P. Cavalcanti et al., "Total arterial coronary bypass graft surgery is associated with better long-term survival in patients with multivessel coronary artery disease: a systematic review with meta-analysis," *Brazilian Journal of Cardiovascular Surgery*, vol. 36, no. 1, pp. 78–85, 2021.
- [22] M. S. Cumpston, J. E. McKenzie, V. A. Welch, and S. E. Brennan, "Strengthening systematic reviews in public health: guidance in the *Cochrane Handbook for Systematic Reviews of Interventions*, 2nd edition," *Journal of Public Health*, vol. 44, no. 4, pp. e588–e592, 2022.
- [23] S. García-Oreja, F. J. Alvaro-Afonso, Y. García-Álvarez, E. García-Morales, I. Sanz-Corbalán, and J. L. Lázaro Martínez, "Topical treatment for plantar warts: a systematic review," *Dermatologic Therapy*, vol. 34, no. 1, Article ID e14621, 2021.
- [24] C. S. Kwok, R. Holland, and S. Gibbs, "Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials," *British Journal of Dermatology*, vol. 165, no. 2, pp. 233–246, 2011.
- [25] C. S. Kwok, S. Gibbs, C. Bennett, R. Holland, and R. Abbott, "Topical treatments for cutaneous warts," *Cochrane Database* of Systematic Reviews, vol. 2012, no. 9, p. CD001781, 2012.
- [26] K. Truong, J. Joseph, B. Manago, and T. Wain, "Destructive therapies for cutaneous warts: a review of the evidence," *AJGP: Australian journal of general practice*, vol. 51, no. 10, pp. 799–803, 2022.
- [27] K. Huang, M. Li, Y. Xiao et al., "The application of medical scale in the treatment of plantar warts: analysis and prospect," *Journal of Dermatological Treatment*, vol. 33, no. 2, pp. 637– 642, 2022.
- [28] Z. Cao, C. Han, B. Qu, and Y. Liu, "The combination treatment of ozone water, superficial shaving, and photodynamic therapy in recalcitrant plantar warts: a successful case," *Photodiagnosis and Photodynamic Therapy*, vol. 39, Article ID 102968, 2022.